The Supporting Role of Hyperbaric Oxygen Therapy in Atopic Dermatitis Treatment
- PMID: 40364168
- PMCID: PMC12072933
- DOI: 10.3390/jcm14093138
The Supporting Role of Hyperbaric Oxygen Therapy in Atopic Dermatitis Treatment
Abstract
Over the past decades, atopic diseases have emerged as a growing global health concern. The Global Report on Atopic Dermatitis 2022 estimated that approximately 223 million people worldwide were living with atopic dermatitis in 2022, with around 43 million being children or adolescents. The financial burden associated with the treatment of this condition poses a significant challenge for both healthcare systems and patients. The current therapeutic approach for atopic diseases primarily focuses on symptomatic management, aiming to mitigate the effects of an overactive immune system. The most widely used treatments include topical or systemic corticosteroids, which suppress inflammation, and emollients, which help restore the skin barrier function. However, prolonged corticosteroid use is associated with adverse effects, including impaired immune response and reduced ability to combat external and internal threats. Consequently, there is a growing interest in developing alternative therapeutic strategies for managing atopic dermatitis. Among these emerging treatments, hyperbaric oxygen therapy (HBOT) appears particularly promising. HBOT has a beneficial effect on the vascular and immune systems, which results in improved functioning of tissues and organs. This therapy has demonstrated efficacy in promoting wound healing, particularly in conditions such as thermal burns and diabetic foot ulcers. Given these properties, HBOT is being tested as a potential adjunctive therapy for atopic dermatitis and other allergy-related diseases. In this paper, we present the current state of knowledge regarding the application of HBOT in the treatment of atopic and immune-mediated conditions, with a focus on its immunomodulatory and regenerative effects.
Keywords: HBOT; atopic dermatitis; immune system; immunomodulation; supporting therapy.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Hyperbaric oxygen therapy for non-healing ulcers in diabetes mellitus: an evidence-based analysis.Ont Health Technol Assess Ser. 2005;5(11):1-28. Epub 2005 Sep 1. Ont Health Technol Assess Ser. 2005. PMID: 23074462 Free PMC article.
-
Poorly designed research does not help clarify the role of hyperbaric oxygen in the treatment of chronic diabetic foot ulcers.Diving Hyperb Med. 2016 Sep;46(3):133-134. Diving Hyperb Med. 2016. PMID: 27723012
-
Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcers: A Health Technology Assessment.Ont Health Technol Assess Ser. 2017 May 12;17(5):1-142. eCollection 2017. Ont Health Technol Assess Ser. 2017. PMID: 28572866 Free PMC article. Review.
-
Therapy of atopic eczema.GMS Health Technol Assess. 2006 Oct 6;2:Doc19. GMS Health Technol Assess. 2006. PMID: 21289970 Free PMC article.
-
Atopic dermatitis and its relation to food allergy.Curr Opin Allergy Clin Immunol. 2020 Jun;20(3):305-310. doi: 10.1097/ACI.0000000000000638. Curr Opin Allergy Clin Immunol. 2020. PMID: 32109909 Review.
References
-
- Asher M.I., Montefort S., Björkstén B., Lai C.K.W., Strachan D.P., Weiland S.K., Williams H. ISAAC Phase Three Study Group Worldwide Time Trends in the Prevalence of Symptoms of Asthma, Allergic Rhinoconjunctivitis, and Eczema in Childhood: ISAAC Phases One and Three Repeat Multicountry Cross-Sectional Surveys. Lancet. 2006;368:733–743. doi: 10.1016/S0140-6736(06)69283-0. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous